Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia
Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and d...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
E. N. Kalyuzhnaya [verfasserIn] M.N N. Ponomareva [verfasserIn] I. M. Petrov [verfasserIn] D. A. Karpova [verfasserIn] L. I. Gapon [verfasserIn] T. I. Petelina [verfasserIn] E. I. Yaroslavskaya [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Российский офтальмологический журнал - Real Time Ltd, 2020, 14(2021), 2, Seite 7-13 |
|---|---|
| Übergeordnetes Werk: |
volume:14 ; year:2021 ; number:2 ; pages:7-13 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.21516/2072-0076-2021-14-2-7-13 |
|---|
| Katalog-ID: |
DOAJ083958592 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ083958592 | ||
| 003 | DE-627 | ||
| 005 | 20230501195735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21516/2072-0076-2021-14-2-7-13 |2 doi | |
| 035 | |a (DE-627)DOAJ083958592 | ||
| 035 | |a (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RE1-994 | |
| 100 | 0 | |a E. N. Kalyuzhnaya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. | ||
| 650 | 4 | |a микроциркуляция | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a дислипидемия | |
| 650 | 4 | |a броксинак® | |
| 650 | 4 | |a тиоктовая кислота | |
| 650 | 4 | |a эмоксипин ® конфликт интересов:отсутствует. | |
| 653 | 0 | |a Ophthalmology | |
| 700 | 0 | |a M.N N. Ponomareva |e verfasserin |4 aut | |
| 700 | 0 | |a I. M. Petrov |e verfasserin |4 aut | |
| 700 | 0 | |a D. A. Karpova |e verfasserin |4 aut | |
| 700 | 0 | |a L. I. Gapon |e verfasserin |4 aut | |
| 700 | 0 | |a T. I. Petelina |e verfasserin |4 aut | |
| 700 | 0 | |a E. I. Yaroslavskaya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Российский офтальмологический журнал |d Real Time Ltd, 2020 |g 14(2021), 2, Seite 7-13 |w (DE-627)176061162X |x 25875760 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:2 |g pages:7-13 |
| 856 | 4 | 0 | |u https://doi.org/10.21516/2072-0076-2021-14-2-7-13 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 |z kostenfrei |
| 856 | 4 | 0 | |u https://roj.igb.ru/jour/article/view/648 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2072-0076 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2587-5760 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 2 |h 7-13 | ||
| author_variant |
e n k enk m n p mnp i m p imp d a k dak l i g lig t i p tip e i y eiy |
|---|---|
| matchkey_str |
article:25875760:2021----::toahgntchrpefcoteircruainfhblacnucianainsihylpdm |
| hierarchy_sort_str |
2021 |
| callnumber-subject-code |
RE |
| publishDate |
2021 |
| allfields |
10.21516/2072-0076-2021-14-2-7-13 doi (DE-627)DOAJ083958592 (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 DE-627 ger DE-627 rakwb rus RE1-994 E. N. Kalyuzhnaya verfasserin aut Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует. Ophthalmology M.N N. Ponomareva verfasserin aut I. M. Petrov verfasserin aut D. A. Karpova verfasserin aut L. I. Gapon verfasserin aut T. I. Petelina verfasserin aut E. I. Yaroslavskaya verfasserin aut In Российский офтальмологический журнал Real Time Ltd, 2020 14(2021), 2, Seite 7-13 (DE-627)176061162X 25875760 nnns volume:14 year:2021 number:2 pages:7-13 https://doi.org/10.21516/2072-0076-2021-14-2-7-13 kostenfrei https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 kostenfrei https://roj.igb.ru/jour/article/view/648 kostenfrei https://doaj.org/toc/2072-0076 Journal toc kostenfrei https://doaj.org/toc/2587-5760 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 14 2021 2 7-13 |
| spelling |
10.21516/2072-0076-2021-14-2-7-13 doi (DE-627)DOAJ083958592 (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 DE-627 ger DE-627 rakwb rus RE1-994 E. N. Kalyuzhnaya verfasserin aut Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует. Ophthalmology M.N N. Ponomareva verfasserin aut I. M. Petrov verfasserin aut D. A. Karpova verfasserin aut L. I. Gapon verfasserin aut T. I. Petelina verfasserin aut E. I. Yaroslavskaya verfasserin aut In Российский офтальмологический журнал Real Time Ltd, 2020 14(2021), 2, Seite 7-13 (DE-627)176061162X 25875760 nnns volume:14 year:2021 number:2 pages:7-13 https://doi.org/10.21516/2072-0076-2021-14-2-7-13 kostenfrei https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 kostenfrei https://roj.igb.ru/jour/article/view/648 kostenfrei https://doaj.org/toc/2072-0076 Journal toc kostenfrei https://doaj.org/toc/2587-5760 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 14 2021 2 7-13 |
| allfields_unstemmed |
10.21516/2072-0076-2021-14-2-7-13 doi (DE-627)DOAJ083958592 (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 DE-627 ger DE-627 rakwb rus RE1-994 E. N. Kalyuzhnaya verfasserin aut Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует. Ophthalmology M.N N. Ponomareva verfasserin aut I. M. Petrov verfasserin aut D. A. Karpova verfasserin aut L. I. Gapon verfasserin aut T. I. Petelina verfasserin aut E. I. Yaroslavskaya verfasserin aut In Российский офтальмологический журнал Real Time Ltd, 2020 14(2021), 2, Seite 7-13 (DE-627)176061162X 25875760 nnns volume:14 year:2021 number:2 pages:7-13 https://doi.org/10.21516/2072-0076-2021-14-2-7-13 kostenfrei https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 kostenfrei https://roj.igb.ru/jour/article/view/648 kostenfrei https://doaj.org/toc/2072-0076 Journal toc kostenfrei https://doaj.org/toc/2587-5760 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 14 2021 2 7-13 |
| allfieldsGer |
10.21516/2072-0076-2021-14-2-7-13 doi (DE-627)DOAJ083958592 (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 DE-627 ger DE-627 rakwb rus RE1-994 E. N. Kalyuzhnaya verfasserin aut Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует. Ophthalmology M.N N. Ponomareva verfasserin aut I. M. Petrov verfasserin aut D. A. Karpova verfasserin aut L. I. Gapon verfasserin aut T. I. Petelina verfasserin aut E. I. Yaroslavskaya verfasserin aut In Российский офтальмологический журнал Real Time Ltd, 2020 14(2021), 2, Seite 7-13 (DE-627)176061162X 25875760 nnns volume:14 year:2021 number:2 pages:7-13 https://doi.org/10.21516/2072-0076-2021-14-2-7-13 kostenfrei https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 kostenfrei https://roj.igb.ru/jour/article/view/648 kostenfrei https://doaj.org/toc/2072-0076 Journal toc kostenfrei https://doaj.org/toc/2587-5760 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 14 2021 2 7-13 |
| allfieldsSound |
10.21516/2072-0076-2021-14-2-7-13 doi (DE-627)DOAJ083958592 (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 DE-627 ger DE-627 rakwb rus RE1-994 E. N. Kalyuzhnaya verfasserin aut Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует. Ophthalmology M.N N. Ponomareva verfasserin aut I. M. Petrov verfasserin aut D. A. Karpova verfasserin aut L. I. Gapon verfasserin aut T. I. Petelina verfasserin aut E. I. Yaroslavskaya verfasserin aut In Российский офтальмологический журнал Real Time Ltd, 2020 14(2021), 2, Seite 7-13 (DE-627)176061162X 25875760 nnns volume:14 year:2021 number:2 pages:7-13 https://doi.org/10.21516/2072-0076-2021-14-2-7-13 kostenfrei https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 kostenfrei https://roj.igb.ru/jour/article/view/648 kostenfrei https://doaj.org/toc/2072-0076 Journal toc kostenfrei https://doaj.org/toc/2587-5760 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 14 2021 2 7-13 |
| language |
Russian |
| source |
In Российский офтальмологический журнал 14(2021), 2, Seite 7-13 volume:14 year:2021 number:2 pages:7-13 |
| sourceStr |
In Российский офтальмологический журнал 14(2021), 2, Seite 7-13 volume:14 year:2021 number:2 pages:7-13 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует. Ophthalmology |
| isfreeaccess_bool |
true |
| container_title |
Российский офтальмологический журнал |
| authorswithroles_txt_mv |
E. N. Kalyuzhnaya @@aut@@ M.N N. Ponomareva @@aut@@ I. M. Petrov @@aut@@ D. A. Karpova @@aut@@ L. I. Gapon @@aut@@ T. I. Petelina @@aut@@ E. I. Yaroslavskaya @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
176061162X |
| id |
DOAJ083958592 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ083958592</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501195735.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21516/2072-0076-2021-14-2-7-13</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ083958592</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJea201c143ad34c7ebfd8d818050cc665</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. N. Kalyuzhnaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">микроциркуляция</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">дислипидемия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">броксинак®</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">тиоктовая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">эмоксипин ® конфликт интересов:отсутствует.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M.N N. Ponomareva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. M. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. A. Karpova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. I. Gapon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. I. Petelina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. I. Yaroslavskaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Российский офтальмологический журнал</subfield><subfield code="d">Real Time Ltd, 2020</subfield><subfield code="g">14(2021), 2, Seite 7-13</subfield><subfield code="w">(DE-627)176061162X</subfield><subfield code="x">25875760</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:7-13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21516/2072-0076-2021-14-2-7-13</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://roj.igb.ru/jour/article/view/648</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-0076</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-5760</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="h">7-13</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
E. N. Kalyuzhnaya |
| spellingShingle |
E. N. Kalyuzhnaya misc RE1-994 misc микроциркуляция misc covid-19 misc дислипидемия misc броксинак® misc тиоктовая кислота misc эмоксипин ® конфликт интересов:отсутствует. misc Ophthalmology Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia |
| authorStr |
E. N. Kalyuzhnaya |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176061162X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RE1-994 |
| illustrated |
Not Illustrated |
| issn |
25875760 |
| topic_title |
RE1-994 Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia микроциркуляция covid-19 дислипидемия броксинак® тиоктовая кислота эмоксипин ® конфликт интересов:отсутствует |
| topic |
misc RE1-994 misc микроциркуляция misc covid-19 misc дислипидемия misc броксинак® misc тиоктовая кислота misc эмоксипин ® конфликт интересов:отсутствует. misc Ophthalmology |
| topic_unstemmed |
misc RE1-994 misc микроциркуляция misc covid-19 misc дислипидемия misc броксинак® misc тиоктовая кислота misc эмоксипин ® конфликт интересов:отсутствует. misc Ophthalmology |
| topic_browse |
misc RE1-994 misc микроциркуляция misc covid-19 misc дислипидемия misc броксинак® misc тиоктовая кислота misc эмоксипин ® конфликт интересов:отсутствует. misc Ophthalmology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Российский офтальмологический журнал |
| hierarchy_parent_id |
176061162X |
| hierarchy_top_title |
Российский офтальмологический журнал |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176061162X |
| title |
Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia |
| ctrlnum |
(DE-627)DOAJ083958592 (DE-599)DOAJea201c143ad34c7ebfd8d818050cc665 |
| title_full |
Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia |
| author_sort |
E. N. Kalyuzhnaya |
| journal |
Российский офтальмологический журнал |
| journalStr |
Российский офтальмологический журнал |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
7 |
| author_browse |
E. N. Kalyuzhnaya M.N N. Ponomareva I. M. Petrov D. A. Karpova L. I. Gapon T. I. Petelina E. I. Yaroslavskaya |
| container_volume |
14 |
| class |
RE1-994 |
| format_se |
Elektronische Aufsätze |
| author-letter |
E. N. Kalyuzhnaya |
| doi_str_mv |
10.21516/2072-0076-2021-14-2-7-13 |
| author2-role |
verfasserin |
| title_sort |
etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after covid-19 associated pneumonia |
| callnumber |
RE1-994 |
| title_auth |
Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia |
| abstract |
Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. |
| abstractGer |
Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. |
| abstract_unstemmed |
Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia |
| url |
https://doi.org/10.21516/2072-0076-2021-14-2-7-13 https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665 https://roj.igb.ru/jour/article/view/648 https://doaj.org/toc/2072-0076 https://doaj.org/toc/2587-5760 |
| remote_bool |
true |
| author2 |
M.N N. Ponomareva I. M. Petrov D. A. Karpova L. I. Gapon T. I. Petelina E. I. Yaroslavskaya |
| author2Str |
M.N N. Ponomareva I. M. Petrov D. A. Karpova L. I. Gapon T. I. Petelina E. I. Yaroslavskaya |
| ppnlink |
176061162X |
| callnumber-subject |
RE - Ophthalmology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.21516/2072-0076-2021-14-2-7-13 |
| callnumber-a |
RE1-994 |
| up_date |
2024-07-03T20:22:24.486Z |
| _version_ |
1803590717394649088 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ083958592</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501195735.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21516/2072-0076-2021-14-2-7-13</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ083958592</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJea201c143ad34c7ebfd8d818050cc665</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. N. Kalyuzhnaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">микроциркуляция</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">дислипидемия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">броксинак®</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">тиоктовая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">эмоксипин ® конфликт интересов:отсутствует.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M.N N. Ponomareva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. M. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. A. Karpova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. I. Gapon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. I. Petelina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. I. Yaroslavskaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Российский офтальмологический журнал</subfield><subfield code="d">Real Time Ltd, 2020</subfield><subfield code="g">14(2021), 2, Seite 7-13</subfield><subfield code="w">(DE-627)176061162X</subfield><subfield code="x">25875760</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:7-13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21516/2072-0076-2021-14-2-7-13</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ea201c143ad34c7ebfd8d818050cc665</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://roj.igb.ru/jour/article/view/648</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-0076</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-5760</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="h">7-13</subfield></datafield></record></collection>
|
| score |
7.40129 |